Johnson & Johnson stock has delivered a strong 80.3% return over the last three years, yet the valuation checks send a mixed message, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the broader scorecard is cautious.

• Over the past three years, Johnson & Johnson has returned 80.3%, which puts more pressure on today’s buyers to judge whether that run already prices in much of the good news.
• Progress in high value drug programs such as IMAAVY and Tecvayli can support expectations for future cash flows, while ongoing litigation exposure and execution risks around the planned DePuy Synthes spin off may weigh on how much investors are willing to pay for those prospects.
• The stock scores 2 out of 6 on our value checks, which suggests Johnson & Johnson is not a clear bargain when viewed across multiple valuation angles even though the DCF points to it trading about 32.6% below intrinsic value.

The issue now is whether Johnson & Johnson’s recent gains and low value score leave enough margin of safety given what the intrinsic value estimate is signaling.

Is Johnson & Johnson Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at Johnson & Johnson through the lens of the cash it is expected to generate for shareholders. Johnson & Johnson produced about $17.0b of free cash flow over the last twelve months, and the model applies a growing cash flow profile to those starting levels to estimate what that stream could be worth today.

On these assumptions, the DCF points to an intrinsic value of about $390 per share, which is above the current share price and indicates the stock is 32.6% undervalued. The recent CHMP recommendation to extend Tecvayli’s use helps explain why some investors see the current price as conservative relative to the cash flow potential of Johnson & Johnson’s pipeline.

Taken together, the cash flow profile and DCF output indicate that Johnson & Johnson stock currently appears undervalued on these assumptions.

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 32.6%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Does Johnson & Johnson Look Fairly Valued on Earnings?

The P/E ratio is a natural fit for Johnson & Johnson because earnings are still a core yardstick for how investors frame this healthcare giant. Johnson & Johnson currently trades at about 30.1x earnings, compared with an industry average of 15.4x and a peer group average around 28.4x, so the stock sits at a premium to the broader Pharmaceuticals sector but roughly in line with large peers.

The model’s fair P/E ratio for Johnson & Johnson is 28.4x, which reflects what investors might pay given its size, margins, pipeline potential and risk profile. That is only slightly below the current 30.1x, indicating the market is not stretching far beyond this tailored benchmark despite the higher headline premium to the sector.

On the P/E multiple, Johnson & Johnson appears priced roughly in line with what the model suggests is a fair range.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation checks leave off for Johnson & Johnson, spelling out which combinations of future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price, and they sit on Simply Wall St's Community page. Rather than leaning on a single multiple or model, each narrative lays out the assumptions behind its own fair value so you can compare them with Johnson & Johnson's actual results over time.

Community views on Johnson & Johnson sit far apart, with one camp focusing on breadth and pipeline, and the other on structural and legal overhangs.

Bull case: roughly fairly valued

"Scaling across 28 platforms or products, each generating at least US$1b in annual revenue, with multiple brands such as DARZALEX, TREMFYA, CARVYKTI, ERLEADA and SPRAVATO already at high run rates, supports a broad base for potential future revenue and earnings growth rather than reliance on a single product…"

Bear case: roughly fairly valued

"Persistent legal and regulatory exposure, highlighted by the talc litigation and higher litigation costs of US$0.9b in Q4 2025 as well as the planned separation of the Orthopaedics business, could lead to additional settlements, adverse rulings, higher compliance costs or stranded costs…"

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

The Bottom Line

For Johnson & Johnson, the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the market multiple suggests the stock is priced about right relative to peers. The low overall value score signals that the broader set of valuation checks is not as supportive as the DCF alone, so the picture is more nuanced than a simple undervalued label. From here, the key question is whether Johnson & Johnson can convert its pipeline and planned portfolio changes into durable cash flows that outweigh ongoing legal and separation risks, or whether the current discount is the market correctly pricing those uncertainties.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.